The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
The projected business potential is around US$ 1 million in the first year
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
